课题基金 / 基金详情

Developmental Studies of Nucleosidic Anti-RNA Virus Drugs

Developmental Studies of Nucleosidic Anti-RNA Virus Drugs
核苷类抗RNA病毒药物的开发研究
批准号:
01870091
负责人:
MATSUDA Akira
金额:
$4.74万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Developmental Scientific Research (B).
财政年份:
1989
资助国家:
日本
项目状态:
已结题
起止时间:
1989 至 1990

项目摘要

项目成果

MATSUDA Akira的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The only antiviral drugs which have been licensed for the treatment of respiratory virus infections are amantadine (rimantadine) in the prophylaxis or early therapy of influenza A virus infection and ribavirin in the therapy, by aerosol, of severe respiratory syncytial virus (RSV) infections in children. Ribavirin was described almost two decades ago as a broad-spectrum antiviral agent. It has shown clinical efficacy against influenza A and B virus, RSV, parainfluenza virus infections and Lassa fever. In the treatment of orthomyxo-and paramyxovirus infections, and in particular, RSV infections in children, ribavirin can be administered as a small-particle aerosol.We have designed a new series of imidazole derivatives, namely, 5-alkynyl-1-beta-D-ribofuranosylimdazole-4-carboxamides, which can be viewed as close analogs of ribavirin, whereby the N at position 2 of the triazole ring is replaced by a alkynyl-carbon moiety. 5-Ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide (EICAR) is … More the prototype of this class of compounds.The 5-alkynyl-1-beta-D-ribofuranosylimidazole-4-carboxamides were synthesized by Pd-catalyzed cross-coupling reaction of terminal alkynes with with 5-iodo derivatieves, which was easily obtained from AICAR in several steps. Other 5-alkyl and derivatives were also synthesized from the corresponding 5-alkynyl derivatives. Among these, EICAR showed the most potent antiviral activity against poxviruses (vaccinia), togaviruses (Sindbis and Semliki forest), arenaviruses (Junin and Tacaribe), reoviruses (type I), orthomyxoviruses (influenza A and B), and paramyxoviruses (parainfluenza type 3, measles, SSPE, and RSV). Although the antiviral activity spectrum of EICAR is similar to that of ribavirin, the potency by EICAR was about 10-to 100-fold greater than that of ribavirin. In vivo antivaccinia virus activity of EICAR was also examined. When administered daily at a dose of either 10 or 25mg/kg, EICAR effected a significant reduction in the number of vaccinia virus tail lesions, without apparent toxicity for the host. Less
期刊论文(13)
专著(0)
科研奖励(0)
会议论文
E.De Clercq,M.Cools,J.Balzarini,R.Snoeck,T.Ueda,N.Minakawa,and A.Matsuda: "Antiviral activity of 5ーethynylー1ーβーDーribofuranosylimidazoleー4ーcarboxamide and related compounds." Antimicrob.Agents Chemother.,. 35. (1991)
E. De Clercq、M. Cools、J. Balzarini、R. Snoeck、T. Ueda、N. Minakawa 和 A. Matsuda:“5-乙炔基-1-β-Dribofuranosylimidillo-4-carboxamide 及相关化合物的抗病毒活性.” Antimicrob.Agents Chemother.,. 35. (1991)
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
N. Minakawa, T. Sasaki, A. Matsuda, and T. Ueda: "Synthesis and antitumor activities of 5ーethynylimidazoleー4ーcarboxamide and ーcarbonitrile derivatives." Nucleosides Nucleotides,. 9. (1990)
N. Minakawa、T. Sasaki、A. Matsuda 和 T. Ueda:“5-乙炔咪唑-4-甲酰胺和 5-乙腈衍生物的合成和抗肿瘤活性。”9。(1990)
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
松田 彰: "糖部変換ヌクレオシド誘導体合成の最近の進歩" 有機合成化学協会誌. 48. 907-920 (1990)
Akira Matsuda:“糖部分转化的核苷衍生物的合成的最新进展”有机合成化学学会杂志 48. 907-920 (1990)。
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
N. Minakawa, T. Takeda, T. Sasaki, A. Matsuda, and T. Ueda: "Synthesis and antineoplastic activity of 5ーethynylー1ーβーDーribofuranosylimidazoleー4ーcarboxamide (EICAR) and its derivatives." J. Med. Chem.,. 34. 778-786 (1991)
N. Minakawa、T. Takeda、T. Sasaki、A. Matsuda 和 T. Ueda:“5-乙炔基-1-β-Dribofuranosylimidilla-4-carboxamide (EICAR) 及其衍生物的合成和抗肿瘤活性。”医学。,34。778-786(1991)
DOI: --
发表时间:
期刊:
影响因子: --
作者: []
通讯作者:
13
    Methods and methodology for utilising an archaeological site after excavation as cultural resources of the local community
    • 批准号:
      16K03152
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $2.08万
    • 财政年份:
      2016
    • 负责人:
      MATSUDA Akira
    • 依托单位:
    Pathophysiological Analysis of Atopic Glaucoma
    • 批准号:
      24592652
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $3.49万
    • 财政年份:
      2012
    • 负责人:
      MATSUDA Akira
    • 依托单位:
    Targeting of the nuclease-resistant functional oligonucleotides
    • 批准号:
      23249008
    • 项目类别:
      Grant-in-Aid for Scientific Research (A)
    • 资助金额:
      $30.62万
    • 财政年份:
      2011
    • 负责人:
      MATSUDA Akira
    • 依托单位:
    Investigation into the molecular mechanism of the resolution of glucocorticoid resistance in lymphoma.
    海外基金